Riluzole: Clinical Trials

17 trials of Riluzole, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 terminated, 2 recruiting, 2 unknown. 17 Phase 3, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 317Completed 9, Terminated 3, Recruiting 2, Unknown 2, Not yet recruiting 1
Phase 29Completed 4, Terminated 2, Unknown 2, Recruiting 1

Follow Riluzole: new trials by email Literature Review of Riluzole trials Research Report on Riluzole

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS)
Phase 3Not yet recruitingAB Science4122026-01-012025-10-03
Riluzole in Patients With Spinocerebellar Ataxia Type 7
Riluzole, Placebo - SCA7
Phase 2 / Phase 3RecruitingS. Andrea Hospital342021-06-012024-12-02
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
Lenzumestrocel, Riluzole, Placebo Comparator - Amyotrophic Lateral Sclerosis
Phase 3CompletedCorestemchemon, Inc.1232021-02-242026-04-30
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Masitinib (6.0), Riluzole, Placebo - Amyotrophic Lateral Sclerosis
Phase 3RecruitingAB Science4952021-02-022025-09-12
The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules
Huolingshengji Granules, Riluzole tablet - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3UnknownPeking University Third Hospital1442020-06-012021-07-08
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
Riluzole, Placebo - Spinocerebellar Ataxia Type 2
Phase 3CompletedAssistance Publique - Hôpitaux de Paris422018-01-172021-06-21
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
Edaravone, Riluzole - Neuromuscular Diseases
Phase 2 / Phase 3UnknownIsfahan University of Medical Sciences202017-03-162019-03-27
Riluzole in Spinal Cord Injury Study
Riluzole, Placebo - Spinal Cord Injury
Phase 2 / Phase 3TerminatedAOSpine North America Research Network1932013-10-012021-04-19
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
Masitinib (4.5), Riluzole, Placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 2 / Phase 3CompletedAB Science3942013-04-012023-09-29
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)
riluzole, Placebo medication - Cervical Spondylotic Myelopathy
Phase 3CompletedAOSpine North America Research Network2702012-03-012018-11-02
Efficacy of Riluzole in Hereditary Cerebellar Ataxia
riluzole, Placebo comparator - Cerebellar Ataxia
Phase 2 / Phase 3CompletedS. Andrea Hospital602010-04-012015-04-21
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
Olesoxime, Placebo Comparator, Riluzole - Amyotrophic Lateral Sclerosis
Phase 3CompletedHoffmann-La Roche5122009-04-302020-02-25
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Lithium Carbonate, Riluzole, placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3TerminatedMassachusetts General Hospital842009-01-012011-04-19
Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)
Riluzole - SMA
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris1412006-01-012013-02-15
Memantine for Disability in Amyotrophic Lateral Sclerosis (MEDALS)
Memantine (Ebixa), riluzole, Placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3CompletedUniversity of Lisbon632005-07-012009-04-01
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Riluzole - Multiple System Atrophy, Progressive Supranuclear Palsy
Phase 3TerminatedKing's College London8002000-04-012005-12-15
Riluzole in Huntington's Disease
Riluzole - Huntington Disease
Phase 3CompletedSanofi5371999-11-012012-02-17

Conditions studied

Amyotrophic Lateral Sclerosis (9)  ·  Motor Neuron Disease (2)  ·  Spinocerebellar Ataxias (2)  ·  Cerebellar Ataxia (1)  ·  Friedreich Ataxia (1)  ·  Huntington Disease (1)  ·  Multiple System Atrophy (1)  ·  Nerve Degeneration (1)  ·  Neuromuscular Diseases (1)  ·  Spinal Cord Injuries (1)  ·  Supranuclear Palsy, Progressive (1)

Sponsors

AB Science (3)  ·  AOSpine North America Research Network (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  S. Andrea Hospital (2)  ·  Corestemchemon, Inc. (1)  ·  Hoffmann-La Roche (1)  ·  Isfahan University of Medical Sciences (1)  ·  King's College London (1)  ·  Massachusetts General Hospital (1)  ·  Peking University Third Hospital (1)  ·  Sanofi (1)  ·  University of Lisbon (1)

Countries

France (4)  ·  United States (4)  ·  Canada (3)  ·  Italy (3)  ·  Spain (3)  ·  Belgium (2)  ·  Germany (2)  ·  Greece (2)  ·  Portugal (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  China (1)  ·  Denmark (1)  ·  Iran (1)  ·  Israel (1)

Top investigators

Albert Ludolph, MD, PhD (1)  ·  Branko Kopjar, MD (1)  ·  Branko Kopjar, MD, PhD (1)  ·  Dongsheng Fan (1)  ·  Jesus S Mora, MD (1)  ·  Jinsy Andrews, MD (1)  ·  Lorne Zinman, MD, MSc, FRCPC (1)  ·  Mamede de Carvalho, MD (1)  ·  Merit Cudkowicz, MD, MSc (1)  ·  Michael Fehlings, MD (1)  ·  Michael Fehlings, MD, PhD (1)

Results publications

PMID 19029129, PMID 19771175, PMID 20363190, PMID 21386111, PMID 21829612, PMID 22985379, PMID 23295632, PMID 26321318, PMID 26394202, PMID 26714284, PMID 30814647, PMID 33357512, PMID 34433481, PMID 34457038, PMID 35063116, PMID 35585556, PMID 36048877, PMID 37130044, PMID 37279301, PMID 37794802, PMID 38011420, PMID 38197642, PMID 39446982, PMID 40347099, PMID 41086299

NIH funding

2017 (1), U01NS049640 (1)